检查点抑制剂免疫治疗:全身适应证与眼部副作用
本文综述免疫检查点抑制剂的全身适应证及眼部副作用,检索1990至2017年PubMed文献。眼部副作用最常见为葡萄膜炎(1%)和干眼(1-24%),其他包括肌无力、眼眶炎症等;多数炎症性副作用可用局部或眶周皮质类固醇管理,晚期病例需全身皮质类固醇并停用检查点抑制剂。
要点
- 免疫检查点抑制剂通过靶向CTLA-4、PD-1或PD-L1激活T细胞攻击恶性肿瘤,可致自身免疫样副作用。
- 眼部副作用最常见为葡萄膜炎(1%)和干眼(1-24%),其他包括肌无力(19例报告)等。
- 多数炎症性副作用用局部或眶周皮质类固醇管理,晚期需全身皮质类固醇并停用检查点抑制剂。
核心结论
- 检查点抑制剂通过解除对T细胞的抑制增强免疫系统,有自身免疫样副作用风险。
- 眼科医生接诊癌症患者新发眼部症状时,应将免疫相关不良事件纳入鉴别诊断。
研究设计与样本
- 文献综述,检索PubMed 1990年至2017年发表的文献。
主要发现
- 眼部副作用最常见为葡萄膜炎(1%)和干眼(1-24%)。
- 其他副作用包括肌无力(19例报告)、眼眶炎症(11例)、角膜炎(3例)、颅神经麻痹(3例)、视神经病变(2例)、浆液性视网膜脱离(2例)。
- 其他副作用还包括眼外肌肌病(1例)、非典型脉络膜视网膜病变(1例)、免疫性视网膜病变(1例)和神经视网膜炎(1例)。
关键数值与推荐
- 检查点抑制剂靶向CTLA-4(伊匹木单抗)、PD-1(帕博利珠单抗、纳武利尤单抗)或PD-L1(阿替利珠单抗、阿维鲁单抗、度伐利尤单抗)。
- 多数炎症性副作用用局部或眶周皮质类固醇管理,晚期病例需全身皮质类固醇并停用检查点抑制剂治疗。
临床怎么用
- 眼科医生接诊癌症患者新发眼部症状时,应将免疫相关不良事件纳入鉴别诊断。
- 多数炎症性副作用用局部或眶周皮质类固醇管理,晚期病例需全身皮质类固醇并停用检查点抑制剂治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review immune checkpoint inhibitor indications and ophthalmic side effects. METHODS: A literature review was performed using a PubMed search for publications between 1990 and 2017. RESULTS: Immune checkpoint inhibitors are designed to treat system malignancies by targeting one of three ligands, leading to T-cell activation for attack against malignant cells. These ligands (and targeted drug) include cytotoxic T-lymphocyte antigen-4 (CTLA-4, ipilimumab), programmed death protein 1 (PD-1, pembrolizumab, nivolumab), and programmed death ligand-1 (PD-L1, atezolizumab, avelumab, durvalumab). These medications upregulate the immune system and cause autoimmune-like side effects. Ophthalmic side effects most frequently manifest as uveitis (1%) and dry eye (1-24%). Other side effects include myasthenia gravis (n = 19 reports), inflammatory orbitopathy (n = 11), keratitis (n = 3), cranial nerve palsy (n = 3), optic neuropathy (n = 2), serous retinal detachment (n = 2), extraocular muscle myopathy (n = 1), atypical chorioretinal lesions (n = 1), immune retinopathy (n = 1), and neuroretinitis (n = 1). Most inflammatory side effects are managed with topical or periocular corticosteroids, but advanced cases require systemic corticosteroids and cessation of checkpoint inhibitor therapy. CONCLUSION: Checkpoint inhibitors enhance the immune system by releasing inhibition on T cells, with risk of autoimmune-like side effects. Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms.
引用
- Dalvin LA, Shields CL, Orloff M, et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018. PMID: 29689030. doi:10.1097/IAE.0000000000002181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。